# Imlunestrant with or without Abemaciclib in Advanced Breast Cancer

*PRI Rank #2 · Topics and Trends in Most Cited Cancer-related Molecular Pathways Papers, Class of 2026*

*Canonical URL: https://pri.pepkio.com/top-papers/cancer-related-molecular-pathways/2026/rank-2*

| Field | Value |
| --- | --- |
| Rank | #2 |
| 18m citations | 153 |
| Journal | New England Journal of Medicine |
| Year | 2024 |
| DOI | 10.1056/nejmoa2410858 |
| Corresponding authors | Komal L Jhaveri |
| Institution | Memorial Sloan Kettering Cancer Center, United States |

**Ranking page:** [Topics and Trends in Most Cited Cancer-related Molecular Pathways Papers, Class of 2026](https://pri.pepkio.com/top-papers/cancer-related-molecular-pathways/2026)

**Paper link:** [10.1056/nejmoa2410858](https://doi.org/10.1056/nejmoa2410858)

## Topics

imlunestrant · abemaciclib · selective estrogen-receptor degrader · ESR1 mutations · ER-positive breast cancer · HER2-negative breast cancer · advanced breast cancer · aromatase inhibitor · CDK4/6 inhibitor · progression-free survival · brain-penetrant oral agent · endocrine monotherapy · restricted mean survival time · imlunestrant-abemaciclib combination · EMBER-3 trial

## Cite this ranking

```
Pepkio Research Index (PRI). Topics and Trends in Most Cited Cancer-related Molecular Pathways Papers, Class of 2026. https://pri.pepkio.com/top-papers/cancer-related-molecular-pathways/2026. Accessed 2026-10-28.

Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459
```